293 related articles for article (PubMed ID: 19501891)
1. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?
Caire AA; Sun L; Ode O; Stackhouse DA; Maloney K; Donatucci C; Mouraviev V; Polascik TJ; Robertson CN; Albala DM; Moul JW
Urology; 2009 Sep; 74(3):643-7. PubMed ID: 19501891
[TBL] [Abstract][Full Text] [Related]
2. Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy.
Xu DD; Sun SD; Wang F; Sun L; Stackhouse D; Polascik T; Albala DM; Moul JW; Caire A; Robertson CN
Urology; 2009 Sep; 74(3):654-8. PubMed ID: 19628263
[TBL] [Abstract][Full Text] [Related]
3. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
[TBL] [Abstract][Full Text] [Related]
4. Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy.
Schroeck FR; Sun L; Freedland SJ; Albala DM; Mouraviev V; Polascik TJ; Moul JW
BJU Int; 2008 Jul; 102(1):28-32. PubMed ID: 18384634
[TBL] [Abstract][Full Text] [Related]
5. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
J Urol; 2008 May; 179(5 Suppl):S53-9. PubMed ID: 18405753
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
[TBL] [Abstract][Full Text] [Related]
7. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.
Schroeck FR; Sun L; Freedland SJ; Jayachandran J; Robertson CN; Moul JW
Prostate Cancer Prostatic Dis; 2008; 11(4):371-6. PubMed ID: 18427570
[TBL] [Abstract][Full Text] [Related]
8. Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen.
Isariyawongse BK; Sun L; Bañez LL; Robertson C; Polascik TJ; Maloney K; Donatucci C; Albala D; Mouraviev V; Madden JF; Moul JW
Urology; 2008 Oct; 72(4):882-6. PubMed ID: 18384857
[TBL] [Abstract][Full Text] [Related]
9. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
[TBL] [Abstract][Full Text] [Related]
10. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
Bañez LL; Sun L; Trock BJ; Han M; Partin AW; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Moul JW; Freedland SJ
J Urol; 2009 Aug; 182(2):491-6; discussion 496-8. PubMed ID: 19524974
[TBL] [Abstract][Full Text] [Related]
11. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
[TBL] [Abstract][Full Text] [Related]
12. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy.
Neuhof D; Hentschel T; Bischof M; Sroka-Perez G; Hohenfellner M; Debus J
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1411-7. PubMed ID: 17275204
[TBL] [Abstract][Full Text] [Related]
13. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH.
King CR; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
Urology; 2007 Apr; 69(4):732-7. PubMed ID: 17445660
[TBL] [Abstract][Full Text] [Related]
14. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
15. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
Shen S; Lepor H; Yaffee R; Taneja SS
J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
Macdonald OK; D'Amico AV; Sadetsky N; Shrieve DC; Carroll PR
Urology; 2007 Jul; 70(1):106-10. PubMed ID: 17656218
[TBL] [Abstract][Full Text] [Related]
17. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
Sun L; Caire AA; Robertson CN; George DJ; Polascik TJ; Maloney KE; Walther PJ; Stackhouse DA; Lack BD; Albala DM; Moul JW
J Urol; 2009 Nov; 182(5):2242-8. PubMed ID: 19758616
[TBL] [Abstract][Full Text] [Related]
18. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
Xylinas E; Drouin SJ; Comperat E; Vaessen C; Renard-Penna R; Misrai V; Bitker MO; Chartier-Kastler E; Richard F; Cussenot O; Roupret M
BJU Int; 2009 May; 103(9):1173-8; discussion 1178. PubMed ID: 19040530
[TBL] [Abstract][Full Text] [Related]
19. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
20. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML
BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]